Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

Jennifer J. Knox; Carlos H. Barrios; Tae Min Kim; Thomas Cosgriff; Vichien Srimuninnimit; Kenneth B. Pittman; Roberto Sabbatini; Sun Young Rha; Thomas W. Flaig; Ray D. Page; J. Thaddeus Beck; Foon yiu Cheung; Sunil Yadav; Poulam M. Patel; Lionnel Geoffrois; Edward Schiff; Julie Niolat; Noah Berkowitz; Maurizio Voi; Robert Motzer

doi:10.1200/JCO.2015.33.15_SUPPL.4554

Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

Jennifer J. Knox
, Carlos H. Barrios
, Tae Min Kim
, Thomas Cosgriff
, Vichien Srimuninnimit
, Kenneth B. Pittman
, Roberto Sabbatini
, Sun Young Rha
, Thomas W. Flaig
, Ray D. Page
, J. Thaddeus Beck
, Foon yiu Cheung
, Sunil Yadav
, Poulam M. Patel
, Lionnel Geoffrois
, Edward Schiff
, Julie Niolat
, Noah Berkowitz
, Maurizio Voi
, Robert Motzer

Princess Margaret Cancer Centre
Pontifícia Universidade Católica do Rio Grande do Sul
Seoul National University Hospital
East Jefferson General Hospital
Siriraj Hospital
Queen Elizabeth Hospital, Woodville, SA, Australia
AOU Policlinico di Modena, Modena, Italy
Yonsei University
University of Colorado Boulder
The Center for Cancer and Blood Disorders, Fort Worth, TX.
Highlands Oncology Group, Fayetteville, AR
Queen Elizabeth Hospital, Kowloon, Hong Kong
University of Saskatchewan
University of Nottingham
Institut de Cancérologie de Lorraine, Vandoeuvre-Lés-Nancy, France
Novartis
Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	33
DOIs	https://doi.org/10.1200/JCO.2015.33.15_SUPPL.4554
State	Published - May 20 2015
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Surgery
Internal Medicine

Access to Document

10.1200/JCO.2015.33.15_SUPPL.4554License: Unspecified

Cite this

Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K. B., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F. Y., Yadav, S., Patel, P. M., Geoffrois, L., Schiff, E., Niolat, J., Berkowitz, N., Voi, M., & Motzer, R. (2015). Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology, 33. https://doi.org/10.1200/JCO.2015.33.15_SUPPL.4554

Knox, JJ, Barrios, CH, Kim, TM, Cosgriff, T, Srimuninnimit, V, Pittman, KB, Sabbatini, R, Rha, SY, Flaig, TW, Page, RD, Beck, JT, Cheung, FY, Yadav, S, Patel, PM, Geoffrois, L, Schiff, E, Niolat, J, Berkowitz, N, Voi, M & Motzer, R 2015, 'Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).', Journal of Clinical Oncology, vol. 33. https://doi.org/10.1200/JCO.2015.33.15_SUPPL.4554

@article{96185998ef4e4314a9cf2c9d76908005,

title = "Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).",

author = "Knox, \{Jennifer J.\} and Barrios, \{Carlos H.\} and Kim, \{Tae Min\} and Thomas Cosgriff and Vichien Srimuninnimit and Pittman, \{Kenneth B.\} and Roberto Sabbatini and Rha, \{Sun Young\} and Flaig, \{Thomas W.\} and Page, \{Ray D.\} and Beck, \{J. Thaddeus\} and Cheung, \{Foon yiu\} and Sunil Yadav and Patel, \{Poulam M.\} and Lionnel Geoffrois and Edward Schiff and Julie Niolat and Noah Berkowitz and Maurizio Voi and Robert Motzer",

note = "4554 Background: RECORD-3 (ClinicalTrials.gov ID, NCT00903175) was a multicenter, randomized phase 2 trial that compared first-line everolimus followed by sunitinib (EVE→SUN) with first-line sunitinib followed by everolimus (SUN→EVE) at progression of disease (PD) in patients with mRCC.",

year = "2015",

month = may,

day = "20",

doi = "10.1200/JCO.2015.33.15\_SUPPL.4554",

language = "American English",

volume = "33",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

AU - Knox, Jennifer J.

AU - Barrios, Carlos H.

AU - Kim, Tae Min

AU - Cosgriff, Thomas

AU - Srimuninnimit, Vichien

AU - Pittman, Kenneth B.

AU - Sabbatini, Roberto

AU - Rha, Sun Young

AU - Flaig, Thomas W.

AU - Page, Ray D.

AU - Beck, J. Thaddeus

AU - Cheung, Foon yiu

AU - Yadav, Sunil

AU - Patel, Poulam M.

AU - Geoffrois, Lionnel

AU - Schiff, Edward

AU - Niolat, Julie

AU - Berkowitz, Noah

AU - Voi, Maurizio

AU - Motzer, Robert

N1 - 4554 Background: RECORD-3 (ClinicalTrials.gov ID, NCT00903175) was a multicenter, randomized phase 2 trial that compared first-line everolimus followed by sunitinib (EVE→SUN) with first-line sunitinib followed by everolimus (SUN→EVE) at progression of disease (PD) in patients with mRCC.

PY - 2015/5/20

Y1 - 2015/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.4554

U2 - 10.1200/JCO.2015.33.15_SUPPL.4554

DO - 10.1200/JCO.2015.33.15_SUPPL.4554

M3 - Article

VL - 33

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

Disciplines

Access to Document

Other files and links

Cite this